Wim Souverijns Sells 10,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Wim Souverijns sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $29.92, for a total value of $299,200.00. Following the completion of the sale, the insider directly owned 45,111 shares in the company, valued at $1,349,721.12. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Pharvaris Stock Up 0.5%

Shares of PHVS stock traded up $0.14 during trading hours on Tuesday, reaching $28.95. 301,435 shares of the company’s stock were exchanged, compared to its average volume of 226,184. Pharvaris N.V. has a fifty-two week low of $15.46 and a fifty-two week high of $33.33. The stock has a market capitalization of $1.89 billion, a P/E ratio of -9.10 and a beta of -2.34. The business has a fifty day moving average price of $28.20 and a 200-day moving average price of $26.63.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, research analysts expect that Pharvaris N.V. will post -3.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PHVS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. UBS Group set a $74.00 price target on Pharvaris in a report on Wednesday, May 13th. Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target for the company. Citizens Jmp cut their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Finally, Citigroup reiterated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Pharvaris currently has a consensus rating of “Moderate Buy” and an average price target of $49.18.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for Pharvaris across multiple quarters and fiscal years, including higher forecasts for FY2026 through FY2030, and maintained a Buy rating with a $60 price target.
• Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, with EPS of ($0.70) versus the consensus estimate of ($0.82), which may support sentiment but does not change the company’s near-term loss profile.
• Negative Sentiment: Insider selling by Director Robert Glassman and insider Wim Souverijns, both of whom sold 10,000 shares, may temper enthusiasm slightly because it can be viewed as reduced insider confidence. SEC filing for Robert Glassman sale SEC filing for Wim Souverijns sale

Institutional Trading of Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System increased its position in shares of Pharvaris by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after purchasing an additional 520 shares during the period. JPMorgan Chase & Co. increased its position in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Pharvaris during the fourth quarter valued at approximately $35,000. Public Employees Retirement System of Ohio increased its position in shares of Pharvaris by 20.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after purchasing an additional 1,300 shares during the period. Finally, Legal & General Group Plc increased its position in shares of Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.